Chrysos Revenue Climbs 33% to $88.1M, Fleet Doubling Next

Chrysos Corporation Ltd (ASX: CHRCF) told its FY 2026 earnings call that revenue rose 33% to $88.1 million with EBITDA up 68%, and that it aims to double its deployed unit fleet over the next three years.

Chrysos Corporation Ltd (ASX: CHRCF) used its FY 2026 earnings call to make a simple argument: the machines it places with mining laboratories are now numerous enough, and busy enough, for the operating leverage in the model to show up in the accounts. Revenue rose 33% to $88.1 million for the year, while EBITDA — earnings before interest, tax, depreciation and amortisation, a rough proxy for cash operating profit — climbed 68%. Management said it is accelerating toward doubling the size of its deployed fleet over the next three years.

The stock last closed at A$4.15, unchanged on the day, with the shares trading in an unbroken A$4.15–A$4.15 range through the session, according to market data as of 20:00 GMT on Monday, 10 August 2026. For context, the broad US benchmarks were similarly becalmed: the S&P 500 tracker closed at $773.03, off 0.03%, the Nasdaq 100 proxy at $720.87, down 0.30%, and the Dow tracker at $538.99, lower by 0.12%.

Why EBITDA grew twice as fast as revenue

The gap between a 33% revenue increase and a 68% EBITDA increase is the whole story of a placement business at scale. Chrysos does not sell its analysers outright in the conventional sense; it deploys units into third-party and mine-site laboratories and earns recurring revenue tied to their use. The heavy costs — engineering, regulatory work, the manufacturing supply chain, the field service organisation — are largely incurred before and around deployment, not each time an additional sample runs through a unit already installed.

That produces a familiar shape. Once a unit is commissioned and its customer’s sample flow ramps, incremental revenue arrives with comparatively little incremental cost attached. Aggregate that across a growing installed base and reported margin expands faster than the top line, which is arithmetically what a 68% EBITDA gain against 33% revenue growth describes. The corollary matters just as much for investors: the same leverage runs in reverse if utilisation stalls or if deployments slip, because the fixed cost base does not shrink on demand.

What doubling the fleet actually requires

A commitment to double deployed units over three years is a capital and execution statement more than a marketing one. Each unit has to be built, shipped, installed in a laboratory that meets the technical and regulatory requirements for the technology, commissioned, and then staffed and supported. Three constraints tend to govern how fast that can happen.

• Manufacturing throughput. Doubling an installed base means the annual build rate has to rise materially and stay there, which draws on working capital before revenue follows.
• Customer laboratory readiness. Deployment timing is often set by the host lab’s construction and permitting schedule rather than by the supplier, which is why guidance in this model is usually framed as units contracted versus units revenue-generating.
• Service coverage. A larger, more geographically dispersed fleet needs field engineers within reach of every site. Support headcount is the cost line most likely to grow ahead of revenue during an expansion phase.

The details of the plan were laid out on the company’s FY 2026 call, as reported by GuruFocus. The company characterised revenue as a record and framed the fleet build as an acceleration rather than a change of direction.

The mining-services backdrop the numbers sit against

Chrysos sells into assay laboratories serving gold and multi-element exploration and production. Demand for that work tracks exploration budgets and mine throughput, both of which have been supported by strength in precious metals — a theme running through much of the mining tape this year, from expansion approvals to record quarters at drilling and lab contractors. When metal prices are firm, miners drill more, sample more and pay for faster turnaround, and laboratory capacity becomes a bottleneck worth spending money to relieve.

That is the cyclical risk embedded in the fleet-doubling plan. A capital programme sized against three years of expected demand is exposed if exploration spending contracts partway through. The offset is contractual: recurring revenue tied to deployed units is stickier than one-off equipment sales, and a lab that has restructured its workflow around a technology does not easily unwind that decision. Investors should want to know how much of the revenue base is minimum-commitment versus purely volume-linked.

What to watch over the next four quarters

With a headline growth rate this high, the follow-through questions are narrow and specific:

• Deployed units versus contracted units. The spread between the two is the clearest early read on whether the doubling timetable is holding.
• Utilisation per unit. Fleet growth flatters revenue even if each machine is doing less work. Revenue per deployed unit is the cleaner measure of demand.
• Whether EBITDA keeps outpacing revenue. A ramp phase can compress margin temporarily as service and manufacturing costs land ahead of revenue. If the margin trend flattens while units grow, that is the ramp, not a deterioration — but it should be explained.
• Funding of the build. Doubling a capital-intensive fleet has to be paid for out of operating cash flow, debt or equity. Which of the three the company leans on will shape per-share outcomes more than the growth rate itself.
• Customer concentration. Rapid fleet growth concentrated among a small number of large laboratory groups carries different risk than the same growth spread across many mine sites.

How the share price fits

The flat A$4.15 close, with no intraday range at all, says nothing about how the market judged the result — it is the print of a session in which the stock barely changed hands rather than a verdict on the numbers. The more meaningful test comes as the fleet build is reported quarter by quarter against the three-year target.

For now, the FY 2026 figures give the bull case its cleanest expression to date: a third more revenue, EBITDA up by more than two-thirds, and a management team willing to commit publicly to doubling the asset base that generates both. The bear case is the same sentence read differently — a cyclical end market, a capital programme sized to optimism, and a cost structure that only rewards shareholders if the machines stay busy.

Key facts

• Share price: A$4.15, unchanged, at the close of 10 Aug 2026 (20:00 GMT)
• FY 2026 revenue: $88.1 million, up 33%
• EBITDA: Up 68% year on year
• Fleet target: Double deployed units over the next three years

Frequently asked questions

What did Chrysos report for FY 2026?

Chrysos Corporation Ltd reported FY 2026 revenue of $88.1 million, a 33% increase, and EBITDA growth of 68%. On its earnings call the company also said it is accelerating toward doubling the size of its deployed analyser fleet over the next three years. Management described the revenue figure as a record for the business.

Why did EBITDA rise faster than revenue?

Chrysos deploys units into laboratories and earns recurring revenue from their use. Most costs are incurred building, shipping and commissioning a unit rather than each time it processes samples. Once a unit is running, added revenue carries little added cost, so profit grows faster than sales across a larger installed base. The leverage also works in reverse.

Where does Chrysos stock trade and at what price?

Chrysos Corporation Ltd trades on the Australian Securities Exchange under the symbol CHRCF. Its most recent close was A$4.15, unchanged from the prior close, with a day range of A$4.15 to A$4.15 as of 20:00 GMT on Monday, 10 August 2026. The market was closed at the time of writing.

What does doubling the deployed fleet involve?

It requires a sustained increase in manufacturing output, customer laboratories that are built and ready to host units, and a larger field service organisation to support a more dispersed base. Each of those consumes capital or headcount before the associated revenue arrives, which is why deployment timing often depends on the customer’s own schedule.

What is the main risk to the growth plan?

Demand depends on mining exploration budgets and mine throughput, which are cyclical and tied to metal prices. A capital programme sized against three years of expected demand is exposed if exploration spending contracts. Recurring, unit-linked revenue is stickier than one-off equipment sales, but utilisation per unit still drives the outcome.

Which metrics should investors track next?

The gap between contracted and revenue-generating units, revenue per deployed unit as a measure of utilisation, whether EBITDA continues to outgrow revenue through the ramp, how the fleet build is funded — cash flow, debt or equity — and how concentrated the customer base becomes as deployments scale.

Sources

• Chrysos Corp Ltd (CHRCF) (FY 2026) Earnings Call Highlights: Record Revenue and Fleet Expansion … — GuruFocus

Photo: https://kaboompics.com/ · Pexels Licence — source